Pentoxifylline for intermittent claudication

Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study

“…Though the exact mechanism is unclear, it has been used in the treatment of intermittent claudication in peripheral arterial disease and venous stasis leg ulcers by decreasing blood viscosity and platelet aggregation. 15 A large study in 2011 investigating 585 eyes showed that the use of antiplatelets and anticoagulants was associated with a poorer visual outcome secondary to more intraretinal hemorrhage in eyes with CRVO and HRVO. 16 Interestingly, a 2007 retrospective study suggested favorable effects of oral pentoxifylline on reducing cystoid macula edema in eyes with CRVO, although VA did not improve in that series.…”

Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study

“…Though the exact mechanism is unclear, it has been used in the treatment of intermittent claudication in peripheral arterial disease and venous stasis leg ulcers by decreasing blood viscosity and platelet aggregation. 15 A large study in 2011 investigating 585 eyes showed that the use of antiplatelets and anticoagulants was associated with a poorer visual outcome secondary to more intraretinal hemorrhage in eyes with CRVO and HRVO. 16 Interestingly, a 2007 retrospective study suggested favorable effects of oral pentoxifylline on reducing cystoid macula edema in eyes with CRVO, although VA did not improve in that series.…”

The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban

“…Its anti‐inflammatory effect is also a result of a competitive nonselective phosphodiesterase inhibition. The recommended dose is 400 mg thrice daily, and combination with other antiplatelet and antifibrinolytic agents enhances its effectiveness …”

Penthoxyfilline Sebagai Terapi Komplementer Chronic Kidney Disease

“…[16] Dosis klinis yang digunakan 400 mg tiga kali sehari. [17] PTX dapat meningkatkan sifat reologi dari darah dengan berbagai cara, seperti penurunan plasma dan viskositas darah. Komulatif dari efek reduksi dalam viskositas plasma, meningkatkan fleksibilitas eritrosit, dan supresi aktivasi neutrophil merupakan peningkatan aliran darah kapiler.…”

Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study

“…Though the exact mechanism is unclear, it has been used in the treatment of intermittent claudication in peripheral arterial disease and venous stasis leg ulcers by decreasing blood viscosity and platelet aggregation. 15 A large study in 2011 investigating 585 eyes showed that the use of antiplatelets and anticoagulants was associated with a poorer visual outcome secondary to more intraretinal hemorrhage in eyes with CRVO and HRVO. 16 Interestingly, a 2007 retrospective study suggested favorable effects of oral pentoxifylline on reducing cystoid macula edema in eyes with CRVO, although VA did not improve in that series.…”

The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban

“…Its anti‐inflammatory effect is also a result of a competitive nonselective phosphodiesterase inhibition. The recommended dose is 400 mg thrice daily, and combination with other antiplatelet and antifibrinolytic agents enhances its effectiveness …”

Penthoxyfilline Sebagai Terapi Komplementer Chronic Kidney Disease

“…[16] Dosis klinis yang digunakan 400 mg tiga kali sehari. [17] PTX dapat meningkatkan sifat reologi dari darah dengan berbagai cara, seperti penurunan plasma dan viskositas darah. Komulatif dari efek reduksi dalam viskositas plasma, meningkatkan fleksibilitas eritrosit, dan supresi aktivasi neutrophil merupakan peningkatan aliran darah kapiler.…”

Clinical Characteristics of Patients With CRVO in One Eye With Subsequent RVO in The Fellow Eye: A Retrospective Observational Study

“…Though the exact mechanism is unclear, it has been used in the treatment of intermittent claudication in peripheral arterial disease and venous stasis leg ulcers by decreasing blood viscosity and platelet aggregation. 15 A large study in 2011 investigating 585 eyes showed that the use of antiplatelets and anticoagulants was associated with a poorer visual outcome secondary to more intraretinal hemorrhage in eyes with CRVO and HRVO. 16 Interestingly, a 2007 retrospective study suggested favorable effects of oral pentoxifylline on reducing cystoid macula edema in eyes with CRVO, although VA did not improve in that series.…”

The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban

“…Its anti‐inflammatory effect is also a result of a competitive nonselective phosphodiesterase inhibition. The recommended dose is 400 mg thrice daily, and combination with other antiplatelet and antifibrinolytic agents enhances its effectiveness …”

Penthoxyfilline Sebagai Terapi Komplementer Chronic Kidney Disease

“…[16] Dosis klinis yang digunakan 400 mg tiga kali sehari. [17] PTX dapat meningkatkan sifat reologi dari darah dengan berbagai cara, seperti penurunan plasma dan viskositas darah. Komulatif dari efek reduksi dalam viskositas plasma, meningkatkan fleksibilitas eritrosit, dan supresi aktivasi neutrophil merupakan peningkatan aliran darah kapiler.…”